Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Nektar In Renal Cell Carcinoma: An Overview
08:18am, Saturday, 10'th Jul 2021
Nektar is developing Bempeg+Opdivo in advanced or metastatic RCC. The company is cash rich and pipeline heavy.
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference
08:30am, Monday, 07'th Jun 2021
SAN FRANCISCO, June 7, 2021 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42nd Annual Globa
SAN FRANCISCO, May 20, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in the Journal of Translational Autoimmunity describing NKTR-358, a
SAN FRANCISCO, May 18, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data from its second major immuno-oncology cytokine program, NKTR-255, i
Nektar (NKTR) Moves 8.5% Higher: Will This Strength Last?
03:46am, Monday, 10'th May 2021
Nektar (NKTR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nektar Therapeutics (NKTR) CEO Howard Robin on Q1 2021 Results - Earnings Call Transcript
12:48pm, Friday, 07'th May 2021
Nektar Therapeutics (NKTR) CEO Howard Robin on Q1 2021 Results - Earnings Call Transcript
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates
06:47pm, Thursday, 06'th May 2021
Nektar (NKTR) delivered earnings and revenue surprises of 5.56% and -18.18%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics Reports First Quarter 2021 Financial Results
04:15pm, Thursday, 06'th May 2021
SAN FRANCISCO, May 6, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2021. Cash and investments in marketable securiti
SAN FRANCISCO, April 27, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2021 on Thursday, May 6, 2021, after the close of U.S.-ba
Nektar (NKTR) Down 10.9% Since Last Earnings Report: Can It Rebound?
12:41pm, Saturday, 27'th Mar 2021
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Nektar Therapeutics Grinding Its Way Toward Pivotal Data
02:34pm, Monday, 08'th Mar 2021
Nektar has two major read-outs coming over the next year, including the early-stage PROPEL study in lung cancer and the PIVOT-IO-001 study in melanoma.
Nektar Therapeutics Stock Likely To See Higher Levels
08:30am, Monday, 01'st Mar 2021
Last month we talked about how Nektar Therapeutics stock seems to be a good buying opportunity, and now there have been more positive developments for the company. Last week, Nektar announced that it
Nektar Therapeutics (NKTR) CEO Howard Robin on Q4 2020 Results - Earnings Call Transcript
03:01am, Friday, 26'th Feb 2021
Nektar Therapeutics (NKTR) CEO Howard Robin on Q4 2020 Results - Earnings Call Transcript
Is a Surprise Coming for Nektar (NKTR) This Earnings Season?
09:54am, Wednesday, 24'th Feb 2021
Nektar (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SAN FRANCISCO, Feb. 18, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2020, on Thursday, February 25, 2
